Microvast Holdings announces departure of chief financial officer
Dwight Gary Gilliland, a director of Labcorp Holdings Inc (NYSE:LH), sold 2,000 shares of common stock on July 30, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a price of $264.95, for a total transaction value of $529,900. The sale comes at a time when the $21.6 billion healthcare services provider maintains a "GOOD" financial health score according to InvestingPro data, with management actively pursuing share buybacks.
Following the transaction, Gilliland directly owns 6,656 shares of Labcorp. The sale was reported on August 1, 2025. While the stock typically demonstrates low price volatility, InvestingPro analysis indicates the company is currently trading near its Fair Value. For deeper insights into Labcorp’s valuation and future prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, Laboratory Corporation of America reported strong financial results for the second quarter of 2025, surpassing analysts’ expectations. The company achieved an adjusted earnings per share of $4.35, exceeding the forecasted $4.17, and recorded revenue of $3.53 billion, above the anticipated $3.48 billion. Following these results, several analyst firms have adjusted their outlooks for Labcorp. Jefferies raised its price target to $300.00 from $290.00, maintaining a Buy rating, citing a 1% top-line beat driven by the Base Business segment. Evercore ISI also increased its price target to $300.00 from $285.00, maintaining an Outperform rating, noting strong diagnostic growth. Additionally, Leerink Partners raised its price target to $323.00 from $293.00, highlighting strength in Labcorp’s diagnostics business and biopharma laboratory services division. These developments reflect a positive sentiment among analysts regarding Labcorp’s recent performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.